Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance
Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger
Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger
View: Text | PDF
Research Article Cell biology Oncology

N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance

  • Text
  • PDF
Abstract

The regulated glycosylation of the proteome has widespread effects on biological processes that cancer cells can exploit. Expression of N-acetylglucosaminyltransferase V (encoded by Mgat5 or GnT-V), which catalyzes the addition of β1,6-linked N-acetylglucosamine to form complex N-glycans, has been linked to tumor growth and metastasis across tumor types. Using a panel of murine pancreatic ductal adenocarcinoma (PDAC) clonal cell lines that recapitulate the immune heterogeneity of PDAC, we found that Mgat5 is required for tumor growth in vivo but not in vitro. Loss of Mgat5 results in tumor clearance that is dependent on T cells and dendritic cells, with NK cells playing an early role. Analysis of extrinsic cell death pathways revealed Mgat5-deficient cells have increased sensitivity to cell death mediated by the TNF superfamily, a property that was shared with other non-PDAC Mgat5-deficient cell lines. Finally, Mgat5 knockout in an immunotherapy-resistant PDAC line significantly decreased tumor growth and increased survival upon immune checkpoint blockade. These findings demonstrate a role for N-glycosylation in regulating the sensitivity of cancer cells to T cell killing through classical cell death pathways.

Authors

Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger

×

Figure 5

Mgat5 glycans protect some non–pancreatic cancer cells against TNF-α–mediated cell death.

Options: View larger image (or click on image) Download as PowerPoint
Mgat5 glycans protect some non–pancreatic cancer cells against TNF-α–med...
(A) Histogram of PHA-L binding, in vitro growth, in vitro cell death assays using TNF-α, and subcutaneous tumor growth of Hep55 EV and Mgat5-KO cells in C57BL/6 mice. For in vitro growth assays, statistical analysis done using 2-way ANOVA with n = 3 replicates per data point for this and all further in vitro growth assays. In vivo growth representative of 2 independent experiments. Analysis for TNF-α death assay done using 2-way ANOVA at 400 ng/mL for this and all further TNF-α death assays at the specified concentration, and representative of 2 independent experiments. Analysis for tumor growth using 2-way ANOVA for this and all further tumor growth curves. Data represent mean ± SEM. (B) Histogram of PHA-L binding, in vitro growth, in vitro cell death assays using TNF-α, and subcutaneous tumor growth of LLC EV and Mgat5-KO cells in C57BL/6 mice. Statistics for TNF-α death assay done at 3.2 ng/mL. (C) Histogram of PHA-L binding, in vitro growth, in vitro cell death assays using TNF-α, and subcutaneous tumor growth of MC38 EV and Mgat5-KO cells in C57BL/6 mice. For in vitro growth assay, n = 6 replicates per data point. Statistics for TNF-α death assay done at 3.2 ng/mL. (D) Histogram of PHA-L binding, in vitro growth, in vitro cell death assays using TNF-α, and subcutaneous tumor growth of B16-F10 EV and Mgat5-KO cells in C57BL/6 mice. Statistics for TNF-α death assay done at 80 ng/mL. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts